CytomX Therapeutics, Inc. Ratios

Ratios Dec2013 Dec2014 Dec2015 Dec2016 Dec2017 Dec2018 Dec2019 Dec2020 Dec2021 Dec2022 Dec2023 Dec2024
Profitability
EBT Margin -1,704.17%-596.81%-458.56%-391.67%-60.89%-118.15%-495.32%-115.06%-310.54%-186.82%3.28%23.24%
EBIT Margin -1,684.23%-586.27%-430.54%-396.10%-64.59%-130.88%-525.92%-117.70%-311.00%-190.61%-6.41%18.10%
EBITDA Margin -1,705.29%-597.01%-459.67%-391.22%-60.27%-142.19%-493.18%-94.88%-311.07%-186.34%-0.48%23.03%
Operating Margin -1,684.23%-586.27%-430.54%-396.10%-64.59%-130.88%-525.92%-117.70%-311.00%-190.61%-6.41%18.10%
Net Margin -2,127.70%-686.94%-545.63%-391.54%-60.17%-142.19%-493.74%-94.73%-310.54%-186.82%-0.56%23.08%
FCF Margin -984.23%593.64%-376.15%-27.97%235.70%-133.29%-535.19%4.31%-323.33%-211.67%-56.19%-62.66%
Efficiency
Assets Average 135.14M198.17M298.39M427.38M399.19M349.97M349.04M300.15M231.34M161.16M
Equity Average -61.41M23.76M102.27M74.19M100.39M78.18M8.85M-4.12M-43.10M-66.60M-23.95M
Invested Capital -44.28M-78.14M126.15M78.48M69.90M130.88M25.47M-7.77M-0.46M-85.75M-47.45M-0.46M
Asset Utilization Ratio 0.060.080.240.140.070.200.110.180.440.86
Leverage & Solvency
Interest Coverage Ratio -58.88-61.12-19.17-35.28
Debt to Equity -0.04
Debt Ratio 0.04
Equity Ratio -1.070.640.390.180.290.07-0.020.00-0.33-0.240.00
Times Interest Earned -58.88-61.12-19.17-35.28
Valuation
Enterprise Value -8.70M-64.40M565.12M218.12M436.70M243.48M81.41M-13.35M-22.70M-87.92M-70.68M-20.02M
Market Capitalization 751.83M400.06M810.81M679.61M377.56M302.77M282.53M105.73M103.83M80.61M
Return Ratios
Return on Sales -17.05%-5.97%-4.59%-3.92%-0.60%-1.42%-4.94%-0.95%-3.11%-1.87%-0.01%0.23%
Return on Capital Employed -0.28%-0.37%-0.19%-0.24%-0.45%-0.29%-0.43%-0.69%-0.09%0.33%
Return on Invested Capital -0.58%-0.62%-1.80%-7.49%-1.04%
Return on Assets -0.26%-0.30%-0.14%-0.20%-0.33%-0.19%-0.33%-0.33%0.00%0.20%
Return on Equity 0.49%-1.49%-0.58%-0.58%-0.84%-1.70%-7.33%28.15%2.30%0.01%-1.33%